One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Coherus BioSciences logo
Coherus BioSciences CHRS
$ 0.37 -5.13%
report update icon

Quarterly report 2026-Q3
added 11-09-2026

Coherus BioSciences Balance Sheet 2025-2011 | CHRS

Brief overview of Coherus BioSciences's balance sheet strength

The review uses the five latest available annual reports between 2021 and 2025.

Assets fell from $679.3 million to $258.3 million. This may reflect either deliberate optimization or a reduction in business scale.

Assets and liabilities changed at similar rates, -62% and -66.1%. The funding mix did not shift sharply.

The equity ratio equals 23.6%, with a starting level of 14.4%. Stable cash flow is important under this structure.

Net debt moved below zero to -$85.6 million, reflecting surplus cash over debt.

The cash share moved from 61.4% to 34.4%. A higher figure generally provides more room in an adverse scenario.

Retained earnings are negative at -$1.4 billion. This reduces the formal capital cushion, although large shareholder returns may have contributed.

What the balance sheet shows

Coherus BioSciences's financial structure is not clear-cut. Asset scale alone does not resolve questions about how those assets are funded.

Annual Balance Sheet Coherus BioSciences

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

-85.6 M -121 M -101 M -59 M -414 M -538 M 11 M 30.7 M -25.1 M -23.8 M -158 M -150 M -35.4 M -12.8 M -

Long Term Debt

1.46 M 3.29 M 351 K 1.42 M 498 K 875 K 178 M 103 M 102 M 100 M - - - - -

Long Term Debt Current

1.83 M 1.69 M 1.42 M 3.13 M 2.75 M 2.57 M 2.2 M - - - - - - - -

Total Non Current Liabilities

56.9 M 298 M 491 M 480 M 416 M 415 M 189 M 105 M 104 M 103 M 113 M 68.7 M 36.1 M 6.09 M -

Total Current Liabilities

140 M 283 M 332 M 139 M 165 M 146 M 115 M 33.3 M 28.4 M 56.4 M 106 M 51.8 M - - -

Total Liabilities

197 M 581 M 823 M 618 M 582 M 561 M 304 M 138 M 132 M 159 M 219 M 120 M 89.8 M 17.3 M -

Deferred Revenue

- - - - - - - - - 1.96 M 51 M 24 M 14.3 M 2.02 M -

Retained Earnings

-1.38 B -1.55 B -1.58 B -1.34 B -1.05 B -763 M -895 M -985 M -775 M -537 M -410 M -187 M -99.6 M -46 M -

Total Assets

258 M 449 M 630 M 481 M 679 M 842 M 409 M 99.5 M 163 M 178 M 212 M 187 M 47.4 M 26.5 M -

Cash and Cash Equivalents

88.9 M 126 M 103 M 63.5 M 417 M 541 M 178 M 72.4 M 127 M 125 M 158 M 150 M 39.6 M 14.5 M -

Book Value

61 M -132 M -193 M -137 M 97.7 M 281 M 105 M -38.6 M 30.5 M 19.4 M -6.93 M 66.8 M -42.4 M 9.19 M -

Total Shareholders Equity

61 M -132 M -193 M -137 M 97.7 M 281 M 105 M -38.6 M 31.8 M 20.5 M -6.21 M 66.8 M -97.1 M -45.5 M -

All numbers in USD currency

Quarterly Balance Sheet Coherus BioSciences

2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

- 459 K - 1.46 M - - - 3.29 M - - - 4.98 M - - - 3.63 M - - - 6.75 M - - 8.38 M 9.07 M 9.74 M 10.4 M 11 M 10.3 M 10.8 M 5.98 M 6.55 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Non Current Liabilities

70.2 M 54.8 M 55.1 M 56.9 M 56.4 M 56 M 299 M 298 M 297 M 296 M 307 M 491 M 478 M 475 M 476 M 480 M 477 M 428 M 427 M 416 M 291 M 296 M 308 M 415 M 415 M 413 M 190 M 189 M 189 M 183 M 183 M 105 M 105 M 104 M 104 M 104 M 103 M 105 M 103 M 103 M 102 M 205 M 200 M 113 M 79.8 M 83.2 M 63.2 M 68.7 M 71.9 M - - - - - - - - - - - - - -

Total Liabilities

146 M 130 M 187 M 197 M 429 M 320 M 555 M 581 M 593 M 759 M 845 M 823 M 717 M 644 M 599 M 618 M 648 M 569 M 581 M 582 M 611 M 583 M 566 M 561 M 548 M 543 M 309 M 304 M 271 M 244 M 225 M 138 M 129 M 126 M 132 M 132 M 135 M 141 M 151 M 159 M 161 M 313 M 293 M 219 M 162 M 153 M 115 M 120 M 120 M 120 M 120 M 89.8 M 89.8 M - - - - - - - - - -

Deferred Revenue

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 669 K 892 K 1.38 M 61.3 M 49.6 M 49.6 M 28.8 M 31 M 22.8 M 22.8 M 25.2 M 22.8 M 22.8 M 14.3 M 14.3 M - - - - - - - - - -

Retained Earnings

-1.48 B -1.44 B -1.42 B -1.38 B -1.35 B -1.31 B -1.61 B -1.55 B -1.5 B -1.49 B -1.48 B -1.58 B -1.5 B -1.46 B -1.42 B -1.34 B -1.28 B -1.2 B -1.15 B -1.05 B -1 B -966 M -936 M -763 M -772 M -800 M -859 M -895 M -934 M -981 M -1 B -985 M -922 M -863 M -820 M -775 M -726 M -667 M -612 M -537 M -461 M -545 M -475 M -410 M -358 M -286 M -227 M -187 M -158 M -187 M -187 M -99.6 M -99.6 M - - - - - - - - - -

Total Assets

171 M 191 M 266 M 258 M 517 M 439 M 371 M 449 M 505 M 675 M 764 M 630 M 584 M 470 M 402 M 481 M 551 M 546 M 593 M 679 M 742 M 740 M 693 M 842 M 804 M 757 M 467 M 409 M 327 M 240 M 186 M 99.5 M 141 M 188 M 128 M 163 M 190 M 172 M 227 M 178 M 192 M 251 M 226 M 212 M 202 M 250 M 153 M 187 M 129 M 187 M 187 M 47.4 M 47.4 M - - - - - - - - - -

Cash and Cash Equivalents

53.6 M 83.2 M 115 M 89.1 M 104 M 217 M 82.7 M 126 M 98 M 160 M 260 M 103 M 80.7 M 73.4 M 16.6 M 64 M 287 M 276 M 326 M 418 M 361 M 330 M 260 M 542 M 293 M 225 M 194 M 178 M 165 M 107 M 82.4 M 73.2 M 102 M 131 M 82.9 M 128 M 136 M 74.2 M 126 M 126 M 160 M 221 M 180 M 159 M 154 M 206 M 115 M 150 M 101 M 150 M 150 M 39.6 M 39.6 M - - 14.5 M - - - 7.68 M - - -

Book Value

25.2 M 60.8 M 78.6 M 61 M 87.8 M 120 M -183 M -132 M -88 M -84.1 M -81.8 M -193 M -134 M -175 M -197 M -137 M -97.1 M -22.6 M 12.6 M 97.7 M 131 M 156 M 128 M 281 M 256 M 213 M 157 M 105 M 56 M -3.98 M -38.5 M -38.6 M 12.4 M 61.8 M -3.09 M 30.5 M 54.9 M 30.9 M 77 M 19.4 M 31.7 M -61.9 M -66.9 M -6.93 M 40 M 96.4 M 38 M 66.8 M 9.18 M 66.8 M 66.8 M -42.4 M -42.4 M - - - - - - - - - -

Total Shareholders Equity

25.2 M 60.8 M 78.6 M 61 M 87.8 M 120 M -183 M -132 M -88 M -84.1 M -81.8 M -193 M -134 M -175 M -197 M -137 M -97.1 M -22.6 M 12.6 M 97.7 M 131 M 156 M 128 M 281 M 256 M 213 M 157 M 105 M 56 M -3.98 M -38.5 M -38.6 M 12.4 M 61.8 M -3.09 M 30.5 M 54.9 M 30.9 M 77 M 19.4 M 31.7 M -61.9 M -66.9 M -6.93 M 40 M 96.4 M 38 M 66.8 M -152 M 66.8 M 66.8 M -97.1 M -97.1 M - - -45.5 M - - - -2.31 M - - -

All numbers in USD currency

Balance Sheet is a fundamental financial report of Coherus BioSciences, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
Aldeyra Therapeutics Aldeyra Therapeutics
ALDX
$ 0.84 16.41 % $ 50.4 M usaUSA
Citius Pharmaceuticals Citius Pharmaceuticals
CTXR
$ 0.51 1.61 % $ 5.64 M usaUSA
Cytokinetics, Incorporated Cytokinetics, Incorporated
CYTK
$ 50.7 -1.48 % $ 6.09 M usaUSA
DBV Technologies S.A. DBV Technologies S.A.
DBVT
$ 9.03 -4.14 % $ 1.26 B franceFrance
Precision BioSciences Precision BioSciences
DTIL
$ 7.37 6.66 % $ 94.5 M usaUSA
Exelixis Exelixis
EXEL
$ 64.59 -1.88 % $ 17.5 B usaUSA
Fennec Pharmaceuticals Fennec Pharmaceuticals
FENC
$ 13.09 -2.68 % $ 374 M usaUSA
Cardiff Oncology Cardiff Oncology
CRDF
$ 0.85 -4.67 % $ 56.8 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 80.87 -0.63 % $ 19.5 B germanyGermany
Alkermes plc Alkermes plc
ALKS
$ 44.89 -2.79 % $ 7.39 B irlandaIrlanda
ANI Pharmaceuticals ANI Pharmaceuticals
ANIP
$ 68.6 -0.77 % $ 1.38 B usaUSA
AIM ImmunoTech AIM ImmunoTech
AIM
$ 0.11 -7.75 % $ 178 K usaUSA
AC Immune SA AC Immune SA
ACIU
$ 1.98 -7.28 % $ 199 M schweizSchweiz
Atara Biotherapeutics Atara Biotherapeutics
ATRA
$ 6.51 2.6 % $ 81.7 M usaUSA
Allogene Therapeutics Allogene Therapeutics
ALLO
$ 0.63 -5.62 % $ 139 M usaUSA
Altimmune Altimmune
ALT
$ 1.33 -6.03 % $ 117 M usaUSA
AnaptysBio AnaptysBio
ANAB
$ 46.65 -1.58 % $ 1.35 B usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 252.39 -1.39 % $ 15.3 B danmarkDanmark
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
$ 7.42 -2.37 % $ 203 M israelIsrael
Aurinia Pharmaceuticals Aurinia Pharmaceuticals
AUPH
$ 14.7 -1.28 % $ 1.98 B canadaCanada
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 0.91 -6.96 % $ 242 M britainBritain
Atea Pharmaceuticals Atea Pharmaceuticals
AVIR
$ 3.97 0.89 % $ 324 M usaUSA
Axsome Therapeutics Axsome Therapeutics
AXSM
$ 129.32 -4.69 % $ 6.43 B usaUSA
BridgeBio Pharma BridgeBio Pharma
BBIO
$ 75.96 -2.84 % $ 14.5 B usaUSA
BioCryst Pharmaceuticals BioCryst Pharmaceuticals
BCRX
$ 7.23 -1.3 % $ 1.52 B usaUSA
Bicycle Therapeutics plc Bicycle Therapeutics plc
BCYC
$ 2.89 -5.25 % $ 200 M britainBritain
Benitec Biopharma Benitec Biopharma
BNTC
$ 7.95 -2.4 % $ 370 M usaUSA
DiaMedica Therapeutics DiaMedica Therapeutics
DMAC
$ 8.24 2.74 % $ 387 M usaUSA
Insmed Incorporated Insmed Incorporated
INSM
$ 141.06 -2.35 % $ 28.1 B usaUSA
Iovance Biotherapeutics Iovance Biotherapeutics
IOVA
$ 6.9 -5.61 % $ 2.47 M usaUSA
CollPlant Biotechnologies Ltd. CollPlant Biotechnologies Ltd.
CLGN
$ 4.64 17.17 % $ 56.6 M israelIsrael
InMed Pharmaceuticals InMed Pharmaceuticals
INM
$ 15.56 13.57 % $ 64.8 M canadaCanada
Biohaven Pharmaceutical Holding Company Ltd. Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$ 12.36 -9.55 % $ 799 M usaUSA
Immutep Limited Immutep Limited
IMMP
$ 3.11 -9.06 % $ 4.53 B australiaAustralia
Jazz Pharmaceuticals plc Jazz Pharmaceuticals plc
JAZZ
$ 228.26 -3.46 % $ 13.9 B irlandaIrlanda
BeyondSpring BeyondSpring
BYSI
$ 0.33 -24.42 % $ 13.6 M usaUSA
Cabaletta Bio Cabaletta Bio
CABA
$ 0.94 -7.24 % $ 94.5 M usaUSA
Johnson & Johnson Johnson & Johnson
JNJ
$ 270.2 1.18 % $ 650 B usaUSA
Cue Biopharma Cue Biopharma
CUE
$ 4.2 -6.67 % $ 398 M usaUSA
C4 Therapeutics C4 Therapeutics
CCCC
$ 2.49 1.84 % $ 206 M usaUSA
Codexis Codexis
CDXS
$ 1.0 -5.17 % $ 87.1 M usaUSA
Kamada Ltd. Kamada Ltd.
KMDA
$ 7.75 -1.02 % $ 447 M israelIsrael
Compugen Ltd. Compugen Ltd.
CGEN
$ 1.83 -2.66 % $ 171 M israelIsrael
Armata Pharmaceuticals Armata Pharmaceuticals
ARMP
$ 3.06 2.68 % $ 111 M usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 27.36 -2.15 % $ 1.82 B usaUSA
Cellectis S.A. Cellectis S.A.
CLLS
$ 0.9 -9.7 % $ 90.3 M franceFrance
Lineage Cell Therapeutics Lineage Cell Therapeutics
LCTX
$ 0.78 -4.87 % $ 179 M usaUSA
Edesa Biotech Edesa Biotech
EDSA
$ 2.01 -7.59 % $ 11.4 M usaUSA